
|Articles|April 1, 1998
Supplements and Featured Publications
- Clinical and Economic Considerations of Coronary Heart Disease: A Managed Care Approach
- Volume 4
- Issue 4 Suppl
Pravastatin Event Reduction Analysis
Author(s)James Shepherd, MD, PhD
Advertisement
Articles in this issue
almost 28 years ago
Participating Facultyalmost 28 years ago
Coronary Heart Disease in the United Statesalmost 28 years ago
Mechanisms of Acute Coronary Eventsalmost 28 years ago
Primary Preventionalmost 28 years ago
Secondary Preventionalmost 28 years ago
Point/Counterpoint: Is LDL-C Reduction the Outcome of Choice?almost 28 years ago
Methods and Mindsets in Pharmacoeconomicsalmost 28 years ago
Issues and Controversies in Pharmacoeconomicsalmost 28 years ago
Pharmacoeconomics Perspectives: Payers, Providers, and PatientsNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Unexplained Pauses Hit Nearly Half of Monthly-Updated CDC Databases, Raising Transparency Concerns
2
ACE Inhibitors Linked to Reduced Mortality in Patients with Idiopathic Pulmonary Fibrosis
3
CRC Becomes Leading Cause of Cancer-Related Death in Younger Adults, Highlighting Prevention Gaps
4
5 Ongoing Phase 3 Trials in Hematologic Malignancies
5










